AstraZeneca resolves Crestor patent spat with Generic Health
Allens 2018-03-01 7:23 pm By Christine Caulfield | Melbourne
Please login to bookmark Close

Pharmaceutical companies AstraZeneca and Generic Health have laid down their swords in a long-running patent dispute over AstraZeneca’s cholesterol drug Crestor, two-and-a-half years after the High Court of Australia found the patent obvious and invalid.

Subscribe to Lawyerly to access this article.

Already a subscriber?
Lost your password?

For information on rights and reprints, contact subscriptions@lawyerly.com.au